{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T13:50:42Z","timestamp":1774705842506,"version":"3.50.1"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40257-018-0342-0","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T01:34:07Z","timestamp":1517535247000},"page":"391-403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Treatment of Autoimmune Bullous Disorders in Pregnancy"],"prefix":"10.1007","volume":"19","author":[{"given":"Carolyn J.","family":"Kushner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef Symon S.","family":"Concha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"issue":"1","key":"342_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ijwd.2015.12.005","volume":"2","author":"CM Blattner","year":"2016","unstructured":"Blattner CM, Danesh M, Safaee M, Murase JE. Understanding the new FDA pregnancy and lactation labeling rules. Int J Women\u2019s Dermatol. 2016;2(1):5.","journal-title":"Int J Women\u2019s Dermatol"},{"issue":"5","key":"342_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/jdv.14101","volume":"31","author":"CC Chi","year":"2017","unstructured":"Chi CC, Kirtschig G, Aberer W, Gabbud JP, Lipozen\u010di\u0107 J, K\u00e1rp\u00e1ti S, et al. Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. J Eur Acad Dermatol Venereol. 2017;31(5):761\u201373.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"342_CR3","first-page":"1","volume":"19","author":"J Hooten","year":"2014","unstructured":"Hooten J, Hall R, Cardones AR. Updates on the management of autoimmune blistering diseases. Skin Ther Lett. 2014;19(5):1\u20136.","journal-title":"Skin Ther Lett."},{"issue":"5","key":"342_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","volume":"346","author":"P Joly","year":"2002","unstructured":"Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321\u20137.","journal-title":"N Engl J Med"},{"issue":"7","key":"342_CR5","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1503\/cmaj.101063","volume":"183","author":"A Hviid","year":"2011","unstructured":"Hviid A, M\u00f8lgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. Can Med Assoc J. 2011;183(7):796\u2013804.","journal-title":"Can Med Assoc J"},{"issue":"3","key":"342_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.clindermatol.2016.02.006","volume":"34","author":"J Wan","year":"2016","unstructured":"Wan J, Imadojemu S, Werth VP. Management of rheumatic and autoimmune blistering disease in pregnancy and postpartum. Clin Dermatol. 2016;34(3):344\u201352.","journal-title":"Clin Dermatol"},{"key":"342_CR7","doi-asserted-by":"crossref","unstructured":"Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. The Cochrane Library. 2015.","DOI":"10.1002\/14651858.CD007346.pub3"},{"issue":"6","key":"342_CR8","first-page":"643","volume":"58","author":"F Alabdulrazzaq","year":"2012","unstructured":"Alabdulrazzaq F, Koren G. Topical corticosteroid use during pregnancy. Can Fam Phys. 2012;58(6):643.","journal-title":"Can Fam Phys"},{"issue":"3","key":"342_CR9","doi-asserted-by":"publisher","first-page":"401.e1","DOI":"10.1016\/j.jaad.2013.09.010","volume":"70","author":"JE Murase","year":"2014","unstructured":"Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70(3):401.e1\u201314.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"342_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1034\/j.1600-0412.2002.810308.x","volume":"81","author":"H Mygind","year":"2002","unstructured":"Mygind H, Thulstrup AM, Pedersen L, Larsen H. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancy. Acta Obstet Gynecol Scand. 2002;81(3):234\u20139.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"Pt 6","key":"342_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/icb.1981.66","volume":"59","author":"J Kulski","year":"1981","unstructured":"Kulski J, Hartmann P. Changes in the concentration of cortisol in milk during different stages of human lactation. Aust J Exp Biol Med Sci. 1981;59(Pt 6):769\u201378.","journal-title":"Aust J Exp Biol Med Sci"},{"issue":"3","key":"342_CR12","doi-asserted-by":"publisher","first-page":"417.e1","DOI":"10.1016\/j.jaad.2013.09.009","volume":"70","author":"DC Butler","year":"2014","unstructured":"Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol. 2014;70(3):417.e1\u201310.","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"342_CR13","first-page":"185","volume":"38","author":"P De Stefano","year":"1983","unstructured":"De Stefano P, Bongo I, Borgna-Pignatti C, Severi F. Factitious hypertension with mineralocorticoid excess in an infant. Helvetica paediatrica Acta. 1983;38(2):185\u20139.","journal-title":"Helvetica paediatrica Acta."},{"issue":"4","key":"342_CR14","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1046\/j.1365-2133.2003.05260.x","volume":"148","author":"G Vecchietti","year":"2003","unstructured":"Vecchietti G, Kerl K, H\u00fcgli A, Samson J, Borradori L. Topical tacrolimus (FK506) for relapsing erosive stomatitis in paraneoplastic pemphigus. Br J Dermatol. 2003;148(4):833\u20134.","journal-title":"Br J Dermatol"},{"issue":"6","key":"342_CR15","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1365-2230.2004.01619.x","volume":"29","author":"T Assmann","year":"2004","unstructured":"Assmann T, Becker J, Ruzicka T, Megahed M. Topical tacrolimus for oral cicatricial pemphigoid. Clin Exp Dermatol. 2004;29(6):674\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"342_CR16","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1365-2133.2004.05835.x","volume":"150","author":"A Chuh","year":"2004","unstructured":"Chuh A. The application of topical tacrolimus in vesicular pemphigoid. Br J Dermatol. 2004;150(3):622\u20133.","journal-title":"Br J Dermatol"},{"issue":"3","key":"342_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2230.2004.01499.x","volume":"29","author":"J Gach","year":"2004","unstructured":"Gach J, Ilchyshyn A. Beneficial effects of topical tacrolimus on recalcitrant erosions of pemphigus vulgaris. Clin Exp Dermatol. 2004;29(3):271\u20132.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"342_CR18","first-page":"684","volume":"9","author":"F Iraji","year":"2010","unstructured":"Iraji F, Asilian A, Siadat AH. Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial. J Drugs Dermatol JDD. 2010;9(6):684\u20136.","journal-title":"J Drugs Dermatol JDD."},{"issue":"Suppl. 1","key":"342_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000102119","volume":"215","author":"T Luger","year":"2007","unstructured":"Luger T, Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology. 2007;215(Suppl. 1):45\u201354.","journal-title":"Dermatology"},{"key":"342_CR20","doi-asserted-by":"publisher","unstructured":"Tyros G, Kalapothakou K, Christofidou E, Kanelleas A, Stavropoulos P. Successful treatment of localized pemphigus foliaceus with topical pimecrolimus. Case Rep Dermatol Med. 2013;2013(2013):489618. https:\/\/doi.org\/10.1155\/2013\/489618","DOI":"10.1155\/2013\/489618"},{"key":"342_CR21","doi-asserted-by":"crossref","unstructured":"Al-Shehhi F, Balakirski G, Baratli J, Leverkus M, Megahed M. Localized oral mucous membrane pemphigoid: successful topical treatment with 1% tacrolimus solution as steroid-sparing therapy. J Eur Acad Dermatol Venereol. 2017; 31(3):e176\u20138.","DOI":"10.1111\/jdv.13894"},{"issue":"11","key":"342_CR22","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/j.1365-4632.2006.02901.x","volume":"45","author":"SN Cohen","year":"2006","unstructured":"Cohen SN, Lim RP, Paul CJ, Abdullah A. Equal efficacy of topical tacrolimus and clobetasone butyrate in pemphigus foliaceus. Int J Dermatol. 2006;45(11):1379.","journal-title":"Int J Dermatol."},{"issue":"4","key":"342_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/dth.12076","volume":"26","author":"I Braunstein","year":"2013","unstructured":"Braunstein I, Werth V. Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy. Dermatol Ther. 2013;26(4):354\u201363.","journal-title":"Dermatol Ther"},{"key":"342_CR24","unstructured":"Sidbury R, Hannifin J. Fitzpatrick\u2019s dermatology in general medicine. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller AS, and Leffell D, editors. Topical Immunomodulators. 7th ed. New York: McGraw-Hill; 2008."},{"key":"342_CR25","doi-asserted-by":"publisher","unstructured":"Rademaker M, Agnew K, Andrews M, Armour K, Baker C, Foley P, et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol. 2017. https:\/\/doi.org\/10.1111\/ajd.12641 .","DOI":"10.1111\/ajd.12641"},{"issue":"2","key":"342_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaad.2016.02.1240","volume":"76","author":"A Caplan","year":"2017","unstructured":"Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: Infectious complications and vaccination recommendations. J Am Acad Dermatol. 2017;76(2):191\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"342_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4274\/jcrpe.v3i3.31","volume":"3","author":"S Kurto\u011flu","year":"2011","unstructured":"Kurto\u011flu S, Sar\u0131c\u0131 D, Ak\u0131n MA, Daar G, Korkmaz L, Memur \u015e. Fetal adrenal suppression due to maternal corticosteroid use: case report. J Clin Res Pediatric Endocrinol. 2011;3(3):160.","journal-title":"J Clin Res Pediatric Endocrinol"},{"key":"342_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.reprotox.2017.02.006","volume":"69","author":"Xiao W-l","year":"2017","unstructured":"W-l Xiao, X-y Liu, Y-s Liu, D-z Zhang, L-f Xue. The relationship between maternal corticosteroid use and orofacial clefts-a meta-analysis. Reprod Toxicol. 2017;69:99\u2013105.","journal-title":"Reprod Toxicol"},{"key":"342_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/CLEP.S46893","volume":"5","author":"AM-B Bj\u00f8rn","year":"2013","unstructured":"Bj\u00f8rn AM-B, Nielsen RB, N\u00f8rgaard M, Nohr EA, Ehrenstein V. Risk of miscarriage among users of corticosteroid hormones: a population-based nested case-control study. Clin Epidemiol. 2013;5:287.","journal-title":"Clin Epidemiol."},{"key":"342_CR30","doi-asserted-by":"crossref","unstructured":"Owa T, Mimura K, Kakigano A, Matsuzaki S, Kumasawa K, Endo M, et al. Pregnancy outcomes in women with different doses of corticosteroid supplementation during labor and delivery. J Obstet Gynaecol Res. 2017;43(7):1132\u20138.","DOI":"10.1111\/jog.13336"},{"key":"342_CR31","volume-title":"Fitzpatrick\u2019s dermatology in general medicine","author":"VP Werth","year":"2008","unstructured":"Werth VP. Systemic Glucocorticoids. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Leffell DF, editors. Fitzpatrick\u2019s dermatology in general medicine. New York: McGraw-Hill; 2008."},{"issue":"8","key":"342_CR32","first-page":"833","volume":"13","author":"R Eming","year":"2015","unstructured":"Eming R, Sticherling M, Hofmann SC, Hunzelmann N, Kern JS, Kramer H, et al. S2\u00a0k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid. JDDG J der Deutschen Dermatologischen Gesellschaft. 2015;13(8):833\u201344.","journal-title":"JDDG J der Deutschen Dermatologischen Gesellschaft."},{"issue":"3","key":"342_CR33","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40265-015-0353-6","volume":"75","author":"CY Zhao","year":"2015","unstructured":"Zhao CY, Murrell DF. Pemphigus vulgaris: an evidence-based treatment update. Drugs. 2015;75(3):271\u201384.","journal-title":"Drugs."},{"key":"342_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.05.002","volume-title":"Antirheumatic drugs in pregnancy and lactation. Seminars in arthritis and rheumatism","year":"2005","unstructured":"Temprano KK, Bandlamudi R, Moore TL, editors. Antirheumatic Drugs in Pregnancy and Lactation. Semin Arthritis Rheum 2005;35(2):112\u201321. https:\/\/doi.org\/10.1016\/j.semarthrit.2005.05.002"},{"key":"342_CR35","first-page":"2163","volume-title":"Cytotoxic and antimetabolic agents. Fitzpatrick\u2019s dermatology in general medicine","author":"WA High","year":"2008","unstructured":"High WA, Fitzpatrick JE. Cytotoxic and antimetabolic agents. Fitzpatrick\u2019s dermatology in general medicine. 7th ed. Philadelphia: McGraw-Hill; 2008. p. 2163\u201381.","edition":"7"},{"key":"342_CR36","doi-asserted-by":"publisher","unstructured":"Huang VW-M, Chang H-J, Kroeker KI, Goodman KJ, Hegadoren KM, Dieleman LA, et al. Management of inflammatory bowel disease during pregnancy and breastfeeding varies widely: a need for further education. Can J Gastroenterol Hepatol. 2016; 2016. https:\/\/doi.org\/10.1155\/2016\/6193275","DOI":"10.1155\/2016\/6193275"},{"issue":"3","key":"342_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.5217\/ir.2015.13.3.193","volume":"13","author":"K-M Lee","year":"2015","unstructured":"Lee K-M, Kim YS, Seo GS, Kim TO, Yang S-K. Diseases ISGotKAftSoI. Use of thiopurines in inflammatory bowel disease: a consensus statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res. 2015;13(3):193\u2013207.","journal-title":"Intest Res"},{"issue":"3","key":"342_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/ar1957","volume":"8","author":"M \u00d8stensen","year":"2006","unstructured":"\u00d8stensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8(3):209.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"342_CR39","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1097\/MIB.0000000000000923","volume":"22","author":"C Mottet","year":"2016","unstructured":"Mottet C, Schoepfer AM, Juillerat P, Cosnes J, Froehlich F, Kessler-Brondolo V, et al. Experts Opinion on the practical use of azathioprine and 6-mercaptopurine in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(11):2733\u201347.","journal-title":"Inflamm Bowel Dis"},{"key":"342_CR40","doi-asserted-by":"publisher","unstructured":"Jharap B, de Boer NK, Stokkers P, Hommes DW, Oldenburg B, Dijkstra G, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut. 2014;63(3):451\u20137. https:\/\/doi.org\/10.1136\/gutjnl-2012-303615 .","DOI":"10.1136\/gutjnl-2012-303615"},{"key":"342_CR41","doi-asserted-by":"publisher","unstructured":"Kanis S, Kreijne J, van der Woude C. Commentary on\u201d Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs. Hum Exp Toxicol. 2017;36(9):993\u20134. https:\/\/doi.org\/10.1177\/0960327116689719 .","DOI":"10.1177\/0960327116689719"},{"issue":"5","key":"342_CR42","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0960327114550882","volume":"34","author":"S Mozaffari","year":"2015","unstructured":"Mozaffari S, Abdolghaffari A, Nikfar S, Abdollahi M. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis. Hum Exp Toxicol. 2015;34(5):445\u201359.","journal-title":"Hum Exp Toxicol"},{"issue":"7","key":"342_CR43","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10067-015-2987-x","volume":"34","author":"M\u00c1 Saavedra","year":"2015","unstructured":"Saavedra M\u00c1, S\u00e1nchez A, Morales S, \u00c1ngeles U, Jara LJ. Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome. Clin Rheumatol. 2015;34(7):1211\u20136.","journal-title":"Clin Rheumatol"},{"key":"342_CR44","doi-asserted-by":"crossref","unstructured":"Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(1):15\u201322.","DOI":"10.1002\/ibd.22948"},{"issue":"3","key":"342_CR45","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1471-0528.1985.tb01088.x","volume":"92","author":"J Davison","year":"1985","unstructured":"Davison J, Dellagrammatikas H, Parkin J. Maternal azathioprine therapy and depressed haemopoiesis in the babies of renal allograft patients. BJOG Int J Obstet Gynaecol. 1985;92(3):233\u20139.","journal-title":"BJOG Int J Obstet Gynaecol"},{"issue":"1","key":"342_CR46","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/apt.12334","volume":"38","author":"T Meij","year":"2013","unstructured":"Meij T, Jharap B, Kneepkens C, Bodegraven A, Boer N. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(1):38\u201343.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"342_CR47","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0190-9622(08)80404-5","volume":"22","author":"AM Layton","year":"1990","unstructured":"Layton AM, Cunliffe WJ. Clearing of epidermolysis bullosa acquisita with cyclosporine. J Am Acad Dermatol. 1990;22(3):535\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"342_CR48","first-page":"20","volume":"8","author":"O Ozdemir","year":"2016","unstructured":"Ozdemir O, Atalay CR, Asgarova V, Ilgin BU. A resistant case of pemphigus gestationis successfully treated with cyclosporine. Interv Med Appl Sci. 2016;8(1):20\u20132.","journal-title":"Interv Med Appl Sci."},{"issue":"5","key":"342_CR49","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40264-013-0034-x","volume":"36","author":"K Paziana","year":"2013","unstructured":"Paziana K, Del Monaco M, Cardonick E, Moritz M, Keller M, Smith B, et al. Ciclosporin use during pregnancy. Drug Saf. 2013;36(5):279\u201394.","journal-title":"Drug Saf"},{"issue":"6","key":"342_CR50","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/aji.12514","volume":"75","author":"R Reggia","year":"2016","unstructured":"Reggia R, Bazzani C, Andreoli L, Motta M, Lojacono A, Zatti S, et al. The efficacy and safety of cyclosporin A in pregnant patients with systemic autoimmune diseases. Am J Reprod Immunol. 2016;75(6):654\u201360.","journal-title":"Am J Reprod Immunol"},{"issue":"5","key":"342_CR51","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jaad.2010.04.039","volume":"64","author":"LK Martin","year":"2011","unstructured":"Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011;64(5):903\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"342_CR52","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/1346-8138.12486","volume":"41","author":"M Amagai","year":"2014","unstructured":"Amagai M, Tanikawa A, Shimizu T, Hashimoto T, Ikeda S, Committee for Guidelines for the Management of Pemphigus D, et al. Japanese guidelines for the management of pemphigus. J Dermatol. 2014;41(6):471\u201386.","journal-title":"J Dermatol."},{"key":"342_CR53","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.intimp.2017.10.027","volume":"53","author":"S Tavakolpour","year":"2017","unstructured":"Tavakolpour S. Current and future treatment options for pemphigus: Is it time to move towards more effective treatments? Int Immunopharmacol. 2017;53:133\u201342.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"342_CR54","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1046\/j.1365-2133.2000.03396.x","volume":"142","author":"TM Finch","year":"2000","unstructured":"Finch TM, Tan CY. Pustular psoriasis exacerbated by pregnancy and controlled by cyclosporin A. Br J Dermatol. 2000;142(3):582\u20134.","journal-title":"Br J Dermatol"},{"issue":"8","key":"342_CR55","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/00007890-200104270-00006","volume":"71","author":"B Bar Oz","year":"2001","unstructured":"Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001;71(8):1051\u20135.","journal-title":"Transplantation"},{"issue":"7","key":"342_CR56","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/ibd.20858","volume":"15","author":"J Branche","year":"2009","unstructured":"Branche J, Cortot A, Bourreille A, Coffin B, de Vos M, de Saussure P, et al. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflamm Bowel Dis. 2009;15(7):1044\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"342_CR57","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/lt.24182","volume":"21","author":"RH Westbrook","year":"2015","unstructured":"Westbrook RH, Yeoman AD, Agarwal K, Aluvihare V, O\u2019Grady J, Heaton N, et al. Outcomes of pregnancy following liver transplantation: the King\u2019s College Hospital experience. Liver Transpl. 2015;21(9):1153\u20139.","journal-title":"Liver Transpl"},{"issue":"1","key":"342_CR58","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0272-6386(85)80138-4","volume":"5","author":"SM Flechner","year":"1985","unstructured":"Flechner SM, Katz AR, Rogers AJ, Vanburen C, Kahan BD. The presence of cyclosporine in body-tissues and fluids during pregnancy. Am J Kidney Dis. 1985;5(1):60\u20133.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"342_CR59","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/bdra.23003","volume":"94","author":"SC Hyoun","year":"2012","unstructured":"Hyoun SC, Obi\u010dan SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A. 2012;94(4):187\u2013207.","journal-title":"Birth Defects Res A"},{"issue":"5","key":"342_CR60","first-page":"S80","volume":"28","author":"E Gromnica-Ihle","year":"2010","unstructured":"Gromnica-Ihle E, Kruger K. Use of methotrexate in young patients with respect to the reproductive system. Clin Exp Rheumatol-Incl Suppl. 2010;28(5):S80.","journal-title":"Clin Exp Rheumatol-Incl Suppl"},{"issue":"5","key":"342_CR61","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/art.38368","volume":"66","author":"C Weber-Schoendorfer","year":"2014","unstructured":"Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Shechtman S, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66(5):1101\u201310.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"342_CR62","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/1756-185X.12860","volume":"19","author":"GS Ngian","year":"2016","unstructured":"Ngian GS, Briggs AM, Ackerman IN, Van Doornum S. Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation. Int J Rheum Dis. 2016;19(9):834\u201343.","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"342_CR63","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/rheumatology\/ket390","volume":"53","author":"C Weber-Schoendorfer","year":"2013","unstructured":"Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, Meister R, Schaefer C. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Rheumatology. 2013;53(4):757\u201363.","journal-title":"Rheumatology"},{"issue":"9","key":"342_CR64","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1177\/0961203316629555","volume":"25","author":"M Noviani","year":"2016","unstructured":"Noviani M, Wasserman S, Clowse M. Breastfeeding in mothers with systemic lupus erythematosus. Lupus. 2016;25(9):973\u20139.","journal-title":"Lupus."},{"issue":"5","key":"342_CR65","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"CG Skorpen","year":"2016","unstructured":"Skorpen CG, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795\u2013810.","journal-title":"Ann Rheum Dis"},{"issue":"02","key":"342_CR66","doi-asserted-by":"publisher","first-page":"042","DOI":"10.1055\/s-0035-1556743","volume":"4","author":"LA Coscia","year":"2015","unstructured":"Coscia LA, Armenti DP, King RW, Sifontis NM, Constantinescu S, Moritz MJ. Update on the teratogenicity of maternal mycophenolate mofetil. J Pediatric Genet. 2015;4(02):042\u201355.","journal-title":"J Pediatric Genet"},{"key":"342_CR67","doi-asserted-by":"crossref","unstructured":"Kylat RI. What is the teratogenic risk of mycophenolate? J Pediatric Genet. 2017;6(2):111\u20134.","DOI":"10.1055\/s-0036-1597933"},{"issue":"3","key":"342_CR68","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ajmg.a.35223","volume":"158","author":"M Hoeltzenbein","year":"2012","unstructured":"Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet Part A. 2012;158(3):588\u201396.","journal-title":"Am J Med Genet Part A."},{"key":"342_CR69","first-page":"1211","volume":"17","author":"P Rengasamy","year":"2016","unstructured":"Rengasamy P. Congenital malformations attributed to prenatal exposure to cyclophosphamide. Anti-Cancer Agents Med Chem. 2017;17(9):1211\u201327.","journal-title":"Anti-Cancer Agents Med Chem."},{"key":"342_CR70","first-page":"237","volume":"86","author":"GM Enns","year":"1999","unstructured":"Enns GM, Roeder E, Chan RT, Catts ZA-K, Cox VA, Golabi M. Apparent cyclophosphamide (Cytoxan). Med Genet. 1999;86:237\u201341.","journal-title":"Med Genet."},{"issue":"7705","key":"342_CR71","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/S0140-6736(71)92474-3","volume":"297","author":"P Wiernik","year":"1971","unstructured":"Wiernik P, Duncan J. Cyclophosphamide in human milk. The Lancet. 1971;297(7705):912.","journal-title":"The Lancet."},{"issue":"11","key":"342_CR72","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1001\/archderm.1992.01680210040004","volume":"128","author":"SR Hymes","year":"1992","unstructured":"Hymes SR, Jordon RE. Pemphigus foliaceus: use of antimalarial agents as adjuvant therapy. Arch Dermatol. 1992;128(11):1462\u20134.","journal-title":"Arch Dermatol"},{"issue":"2","key":"342_CR73","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.autrev.2004.11.009","volume":"4","author":"N Costedoat-Chalumeau","year":"2005","unstructured":"Costedoat-Chalumeau N, Amoura Z, Lechat P, Piette J-C. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev. 2005;4(2):111\u20135.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"342_CR74","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1546-0096-7-9","volume":"7","author":"K Sperber","year":"2009","unstructured":"Sperber K, Hom C, Chao CP, Shapiro D, Ash J. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatric Rheumatol. 2009;7(1):9.","journal-title":"Pediatric Rheumatol"},{"issue":"11","key":"342_CR75","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1002\/art.22159","volume":"54","author":"ME Clowse","year":"2006","unstructured":"Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheumatol. 2006;54(11):3640\u20137.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"342_CR76","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1191\/096120301678646137","volume":"10","author":"R Levy","year":"2001","unstructured":"Levy R, Vilela V, Cataldo M, Ramos R, Duarte JL, Tura B, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10(6):401\u20134.","journal-title":"Lupus."},{"issue":"1","key":"342_CR77","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2515\/therapie\/2013003","volume":"68","author":"N Tarfaoui","year":"2012","unstructured":"Tarfaoui N, Autret-Leca E, Mazjoub S, Cissoko H, Jonville-Bera A-P. Hydroxychloroquine during pregnancy: a review of retinal toxicity in the newborns. Therapie. 2012;68(1):43\u20137.","journal-title":"Therapie."},{"issue":"6","key":"342_CR78","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/11310740-000000000-00000","volume":"10","author":"HM G\u00fcrcan","year":"2009","unstructured":"G\u00fcrcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid. Am J Clin Dermatol. 2009;10(6):383\u201396.","journal-title":"Am J Clin Dermatol"},{"key":"342_CR79","doi-asserted-by":"crossref","unstructured":"Sticherling M, Franke A, Aberer E, Glaser R, Hertl M, Pfeiffer C, et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol. 2017;177(5):1299\u2013305.","DOI":"10.1111\/bjd.15649"},{"issue":"2","key":"342_CR80","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00128071-200506020-00004","volume":"6","author":"C Sacher","year":"2005","unstructured":"Sacher C, Hunzelmann N. Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches. Am J Clin Dermatol. 2005;6(2):93\u2013103.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"342_CR81","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.cden.2013.07.003","volume":"57","author":"HH Xu","year":"2013","unstructured":"Xu HH, Werth VP, Parisi E, Sollecito TP. Mucous membrane pemphigoid. Dent Clin North Am. 2013;57(4):611\u201330.","journal-title":"Dent Clin North Am"},{"issue":"2","key":"342_CR82","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.clindermatol.2015.11.006","volume":"34","author":"KC Broussard","year":"2016","unstructured":"Broussard KC, Leung TG, Moradi A, Thorne JE, Fine JD. Autoimmune bullous diseases with skin and eye involvement: cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica. Clin Dermatol. 2016;34(2):205\u201313.","journal-title":"Clin Dermatol"},{"issue":"9","key":"342_CR83","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/00002018-200427090-00002","volume":"27","author":"BJ Brabin","year":"2004","unstructured":"Brabin BJ, Eggelte TA, Parise M, Verhoeff F. Dapsone therapy for malaria during pregnancy. Drug Saf. 2004;27(9):633\u201348.","journal-title":"Drug Saf"},{"key":"342_CR84","doi-asserted-by":"publisher","unstructured":"Ozturk Z, Tatliparmak A. Leprosy treatment during pregnancy and breastfeeding: a case report and brief review of literature. Dermatol Ther. 2016;30(1). https:\/\/doi.org\/10.1111\/dth.12414 .","DOI":"10.1111\/dth.12414"},{"issue":"1\u20132","key":"342_CR85","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3109\/03602539509029818","volume":"27","author":"DJ Jollow","year":"1995","unstructured":"Jollow DJ, Bradshaw TP, Bradshaw DC. Dapsone-induced hemolytic anemia. Drug Metab Rev. 1995;27(1\u20132):107\u201324.","journal-title":"Drug Metab Rev"},{"issue":"6","key":"342_CR86","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1365-2125.1986.tb02967.x","volume":"22","author":"M Edstein","year":"1986","unstructured":"Edstein M, Veenendaal J, Newman K, Hyslop R. Excretion of chloroquine, dapsone and pyrimethamine in human milk. Br J Clin Pharmacol. 1986;22(6):733\u20135.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"342_CR87","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bjd.13729","volume":"173","author":"J Chalmers","year":"2015","unstructured":"Chalmers J, Wojnarowska F, Kirtschig G, Nunn A, Bratton D, Mason J, et al. A randomized controlled trial to compare the safety and effectiveness of doxycycline (200\u00a0mg daily) with oral prednisolone (0\u00b7 5\u00a0mg\u00a0kg\u2212 daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial. Br J Dermatol. 2015;173(1):227\u201334.","journal-title":"Br J Dermatol"},{"issue":"10079","key":"342_CR88","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","volume":"389","author":"HC Williams","year":"2017","unstructured":"Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017;389(10079):1630\u20138.","journal-title":"Lancet"},{"issue":"3","key":"342_CR89","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1517\/14740338.2016.1133584","volume":"15","author":"R Cross","year":"2016","unstructured":"Cross R, Ling C, Day NP, McGready R, Paris DH. Revisiting doxycycline in pregnancy and early childhood\u2013time to rebuild its reputation? Expert Opin Drug Saf. 2016;15(3):367\u201382.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"342_CR90","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1097\/AOG.0b013e3182a5fdfd","volume":"122","author":"D Meaney-Delman","year":"2013","unstructured":"Meaney-Delman D, Rasmussen SA, Beigi RH, Zotti ME, Hutchings Y, Bower WA, et al. Prophylaxis and Treatment of anthrax in pregnant women: a systematic review of antibiotics. Obstet Gynecol. 2013;122(4):885.","journal-title":"Obstet Gynecol"},{"key":"342_CR91","unstructured":"Solaris. Solaris-summary of product characteristics: UK Electronic Medicines Compendium; 2017 updated 3\/25\/2017. http:\/\/www.medicines.org.uk\/emc\/medicine\/19966\/SPC\/soliris . Accessed 15 Sept 2017."},{"issue":"2","key":"342_CR92","first-page":"85","volume":"62","author":"B Honl","year":"1998","unstructured":"Honl B, Elston D. Autoimmune bullous eruption localized to a breast reconstruction site: response to niacinamide. Cutis. 1998;62(2):85\u20136.","journal-title":"Cutis"},{"key":"342_CR93","doi-asserted-by":"crossref","unstructured":"Abdelmaksoud A. Tetracyclines and\/or nicotinamide in blistering dermatosis. J Eur Acad Dermatol Venereol. 2017;31(6):e291.","DOI":"10.1111\/jdv.14067"},{"issue":"1","key":"342_CR94","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jdv.13779","volume":"31","author":"A K\u00f6ckritz","year":"2017","unstructured":"K\u00f6ckritz A, St\u00e4nder S, Zeidler C, Metze D, Luger T, Bonsmann G. Successful monotherapy of pemphigus vegetans with minocycline and nicotinamide. J Eur Acad Dermatol Venereol. 2017;31(1):85\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"342_CR95","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jaad.2014.04.040","volume":"71","author":"M McCarty","year":"2014","unstructured":"McCarty M, Fivenson D. Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: defining a niche for these low toxicity agents. J Am Acad Dermatol. 2014;71(3):475\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"342_CR96","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/bjd.12072","volume":"167","author":"V Venning","year":"2012","unstructured":"Venning V, Taghipour K, Mohd Mustapa M, Highet A, Kirtschig G. British Association of Dermatologists\u2019 guidelines for the management of bullous pemphigoid 2012. Br J Dermatol. 2012;167(6):1200\u201314.","journal-title":"Br J Dermatol"},{"issue":"3","key":"342_CR97","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1529-8019.2010.01329.x","volume":"23","author":"F Iraji","year":"2010","unstructured":"Iraji F, Banan L. The efficacy of nicotinamide gel 4% as an adjuvant therapy in the treatment of cutaneous erosions of pemphigus vulgaris. Dermatol Ther. 2010;23(3):308\u201311.","journal-title":"Dermatol Ther"},{"issue":"4","key":"342_CR98","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/jocd.12119","volume":"13","author":"HM Rolfe","year":"2014","unstructured":"Rolfe HM. A review of nicotinamide: treatment of skin diseases and potential side effects. J Cosmet Dermatol. 2014;13(4):324\u20138.","journal-title":"J Cosmet Dermatol"},{"issue":"1","key":"342_CR99","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clindermatol.2011.03.011","volume":"30","author":"R Gupta","year":"2012","unstructured":"Gupta R, Woodley DT, Chen M. Epidermolysis bullosa acquisita. Clin Dermatol. 2012;30(1):60\u20139.","journal-title":"Clin Dermatol"},{"key":"342_CR100","doi-asserted-by":"crossref","unstructured":"Machen L, Clowse ME. Vasculitis and pregnancy. Rheum Dis Clin N Am. 2017;43(2):239\u201347.","DOI":"10.1016\/j.rdc.2016.12.005"},{"issue":"2","key":"342_CR101","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1089\/bfm.2014.0086","volume":"10","author":"T Herscovici","year":"2015","unstructured":"Herscovici T, Merlob P, Stahl B, Laron-Kenet T, Klinger G. Colchicine use during breastfeeding. Breastfeeding Med. 2015;10(2):92\u20135.","journal-title":"Breastfeeding Med"},{"issue":"6","key":"342_CR102","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa067752","volume":"357","author":"P Joly","year":"2007","unstructured":"Joly P, Mouquet H, Roujeau J-C, D\u2019incan M, Gilbert D, Jacquot S, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6):545\u201352.","journal-title":"N Engl J Med"},{"issue":"1","key":"342_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2008\/271363","volume":"2008","author":"D Klink","year":"2008","unstructured":"Klink D, Van Elburg R, Schreurs M, Van Well G. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol. 2008;2008(1):1.","journal-title":"Clin Dev Immunol"},{"issue":"5","key":"342_CR104","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","volume":"117","author":"EF Chakravarty","year":"2011","unstructured":"Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499\u2013506.","journal-title":"Blood"},{"issue":"6","key":"342_CR105","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/rheumatology\/kex039","volume":"56","author":"Y Bragnes","year":"2017","unstructured":"Bragnes Y, Boshuizen R, de Vries A, Lexberg \u00c5, \u00d8stensen M. Low level of Rituximab in human breast milk in a patient treated during lactation. Rheumatology. 2017;56(6):1047\u20138.","journal-title":"Rheumatology"},{"issue":"3","key":"342_CR106","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2008.11.035","volume":"123","author":"JA Fairley","year":"2009","unstructured":"Fairley JA, Baum CL, Brandt DS, Messingham KA. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol. 2009;123(3):704\u20135.","journal-title":"J Allergy Clin Immunol."},{"issue":"11","key":"342_CR107","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1001\/archdermatol.2012.1604","volume":"148","author":"VA London","year":"2012","unstructured":"London VA, Kim GH, Fairley JA, Woodley DT. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol. 2012;148(11):1241\u20133.","journal-title":"Arch Dermatol"},{"issue":"5","key":"342_CR108","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/j.1365-2133.2011.10748.x","volume":"166","author":"C Dufour","year":"2012","unstructured":"Dufour C, Souillet AL, Chaneliere C, Jouen F, Bodemer C, Jullien D, et al. Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol. 2012;166(5):1140\u20132.","journal-title":"Br J Dermatol"},{"issue":"10","key":"342_CR109","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/jdv.13758","volume":"30","author":"G Balakirski","year":"2016","unstructured":"Balakirski G, Alkhateeb A, Merk HF, Leverkus M, Megahed M. Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature. J Eur Acad Dermatol Venereol. 2016;30(10):1778\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"342_CR110","doi-asserted-by":"publisher","first-page":"577","DOI":"10.4103\/0378-6323.183628","volume":"82","author":"MZ Gonul","year":"2016","unstructured":"Gonul MZ, Keseroglu HO, Ergin C, Ozcan I, Erdem O. Bullous pemphigoid successfully treated with omalizumab. Indian J Dermatol Venereol Leprol. 2016;82(5):577\u20139.","journal-title":"Indian J Dermatol Venereol Leprol."},{"issue":"3","key":"342_CR111","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","volume":"71","author":"KK Yu","year":"2014","unstructured":"Yu KK, Crew AB, Messingham KA, Fairley JA, Woodley DT. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71(3):468\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"342_CR112","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jaci.2014.08.025","volume":"135","author":"J Namazy","year":"2015","unstructured":"Namazy J, Cabana MD, Scheuerle AE, Thorp JM Jr, Chen H, Carrigan G, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015;135(2):407\u201312.","journal-title":"J Allergy Clin Immunol."},{"issue":"4","key":"342_CR113","first-page":"277","volume":"13","author":"S Grunewald","year":"2015","unstructured":"Grunewald S, Jank A. New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. J Dtsch Dermatol Ges. 2015;13(4):277\u201389 (quiz 90).","journal-title":"J Dtsch Dermatol Ges."},{"issue":"4","key":"342_CR114","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000243805","volume":"219","author":"M Bordignon","year":"2009","unstructured":"Bordignon M, Belloni-Fortina A, Pigozzi B, Tarantello M, Alaibac M. Bullous pemphigoid during long-term TNF-\u03b1 blocker therapy. Dermatology. 2009;219(4):357\u20138.","journal-title":"Dermatology"},{"issue":"3","key":"342_CR115","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000318008","volume":"221","author":"L Boussemart","year":"2010","unstructured":"Boussemart L, Jacobelli S, Batteux F, Goulvestre C, Grange P, Carlotti A, et al. Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports. Dermatology. 2010;221(3):201\u20135.","journal-title":"Dermatology"},{"key":"342_CR116","doi-asserted-by":"crossref","unstructured":"Stausb\u00f8l-Gr\u00f8n B, Deleuran M, Sommer Hansen E, Kragballe K. Development of bullous pemphigoid during treatment of psoriasis with adalimumab. Clin Exp Dermatol. 2009;34(7):e285\u20136.","DOI":"10.1111\/j.1365-2230.2008.03204.x"},{"issue":"3","key":"342_CR117","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bjd.13350","volume":"172","author":"R Hall","year":"2015","unstructured":"Hall R, Fairley J, Woodley D, Werth V, Hannah D, Streilein R, et al. A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br J Dermatol. 2015;172(3):760\u20138.","journal-title":"Br J Dermatol"},{"issue":"10","key":"342_CR118","first-page":"940","volume":"8","author":"A Shetty","year":"2009","unstructured":"Shetty A, Marcum CB, Glass LF, Carter JD. Successful treatment of pemphigus vulgaris with etanercept in four patients. J Drugs Dermatol JDD. 2009;8(10):940\u20133.","journal-title":"J Drugs Dermatol JDD."},{"issue":"12","key":"342_CR119","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1517\/14740338.2014.951326","volume":"13","author":"M Gerosa","year":"2014","unstructured":"Gerosa M, Meroni PL, Cimaz R. Safety considerations when prescribing immunosuppression medication to pregnant women. Expert Opin Drug Saf. 2014;13(12):1591\u20139.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"342_CR120","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jaad.2011.04.030","volume":"65","author":"MM Heller","year":"2011","unstructured":"Heller MM, Wu JJ, Murase JE. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. J Am Acad Dermatol. 2011;65(4):870.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"342_CR121","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/ddg.13013","volume":"15","author":"A Enk","year":"2017","unstructured":"Enk A, Hadaschik E, Eming R, Fierlbeck G, French L, Girolomoni G, et al. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. JDDG J der Deutschen Dermatologischen Gesellschaft. 2017;15(2):228\u201341.","journal-title":"JDDG J der Deutschen Dermatologischen Gesellschaft."},{"issue":"2","key":"342_CR122","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/ajd.12422","volume":"57","author":"D Svecova","year":"2016","unstructured":"Svecova D. IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects. Australas J Dermatol. 2016;57(2):141\u20134.","journal-title":"Australas J Dermatol"},{"issue":"4","key":"342_CR123","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","volume":"60","author":"M Amagai","year":"2009","unstructured":"Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60(4):595\u2013603.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"342_CR124","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2340\/00015555-1471","volume":"93","author":"V Seidling","year":"2013","unstructured":"Seidling V, Hoffmann JHO, Enk AH, Hadascrik EN. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm-Venereol. 2013;93(3):346\u20139.","journal-title":"Acta Derm-Venereol."},{"issue":"1","key":"342_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.intimp.2015.02.038","volume":"26","author":"T Nguyen","year":"2015","unstructured":"Nguyen T, Alraqum E, Ahmed AR. Positive clinical outcome with IVIg as monotherapy in recurrent pemphigoid gestationis. Int Immunopharmacol. 2015;26(1):1\u20133.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"342_CR126","first-page":"272","volume":"72","author":"JG Routsias","year":"2010","unstructured":"Routsias JG, Kyriakidis N, Friedman D, Llanos C, Clancy R, Buyon J, et al. IVIG administration enhances the anti-idiotypic response to the major epitope of La\/SSB autoantigen in pregnant women at high risk for a child with CHB. Scand J Immunol. 2010;72(3):272.","journal-title":"Scand J Immunol"},{"issue":"1","key":"342_CR127","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/aji.12442","volume":"75","author":"SK Lee","year":"2016","unstructured":"Lee SK, Kim JY, Han AR, Hur SE, Kim CJ, Kim TH, et al. Intravenous immunoglobulin G improves pregnancy outcome in women with recurrent pregnancy losses with cellular immune abnormalities. Am J Reprod Immunol. 2016;75(1):59\u201368.","journal-title":"Am J Reprod Immunol"},{"issue":"9","key":"342_CR128","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/j.1468-3083.2010.03925.x","volume":"25","author":"A Ahmed","year":"2011","unstructured":"Ahmed A, G\u00fcrcan H. Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2011;25(9):1073\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"342_CR129","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.rdc.2016.12.002","volume":"43","author":"BL Bermas","year":"2017","unstructured":"Bermas BL. Lactation and management of postpartum disease. Rheum Dis Clin N Am. 2017;43(2):249\u201362. https:\/\/doi.org\/10.1016\/j.rdc.2016.12.002 .","journal-title":"Rheum Dis Clin N Am."},{"issue":"9","key":"342_CR130","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00415-004-0495-z","volume":"251","author":"A Achiron","year":"2004","unstructured":"Achiron A, Kishner I, Dolev M, Stern Y, Dulitzky M, Schiff E, et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol. 2004;251(9):1133\u20137.","journal-title":"J Neurol"},{"key":"342_CR131","doi-asserted-by":"crossref","unstructured":"Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS, et al. Pemphigus. Nat Rev Dis Primers. 2017;3:17026.","DOI":"10.1038\/nrdp.2017.26"},{"issue":"4","key":"342_CR132","doi-asserted-by":"publisher","first-page":"508","DOI":"10.4103\/0378-6323.98092","volume":"78","author":"PSS Ranugha","year":"2012","unstructured":"Ranugha PSS, Kumari R, Kartha LB, Parameswaran S, Thappa DM. Therapeutic plasma exchange as a crisis option in severe pemphigus vulgaris. Indian J Dermatol Ve. 2012;78(4):508\u201310.","journal-title":"Indian J Dermatol Ve."},{"issue":"1","key":"342_CR133","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1473-0502(02)00095-2","volume":"28","author":"G Mazzi","year":"2003","unstructured":"Mazzi G, Raineri A, Zanolli FA, Da Ponte C, De Roia D, Santarossa L, et al. Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. Transfus Apheres Sci. 2003;28(1):13\u20138.","journal-title":"Transfus Apheres Sci"},{"issue":"1","key":"342_CR134","first-page":"27","volume":"9","author":"M Marker","year":"2011","unstructured":"Marker M, Derfler K, Monshi B, Rappersberger K. Successful immunoapheresis of bullous autoimmune diseases: pemphigus vulgaris and pemphigoid gestationis. JDDG J der Deutschen Dermatologischen Gesellschaft. 2011;9(1):27\u201331.","journal-title":"JDDG J der Deutschen Dermatologischen Gesellschaft."},{"issue":"3","key":"342_CR135","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ijgo.2007.05.045","volume":"99","author":"D El-Haieg","year":"2007","unstructured":"El-Haieg D, Zanati M, El-Foual F. Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int J Gynecol Obstet. 2007;99(3):236\u201341.","journal-title":"Int J Gynecol Obstet"},{"issue":"2","key":"342_CR136","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.rdc.2007.02.005","volume":"33","author":"PM Izmirly","year":"2007","unstructured":"Izmirly PM, Rivera TL, Buyon JP. Neonatal lupus syndromes. Rheum Dise Clin N Am. 2007;33(2):267\u201385.","journal-title":"Rheum Dise Clin N Am"},{"issue":"22","key":"342_CR137","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1080\/14767058.2016.1262344","volume":"30","author":"M Jak\u00f3","year":"2016","unstructured":"Jak\u00f3 M, Sur\u00e1nyi A, Jan\u00e1ky M, Kliv\u00e9nyi P, Kaizer L, V\u00e9csei L, et al. Postnatal outcome and placental blood flow after plasmapheresis during pregnancy. J Mater Fetal Neonatal Med. 2017;30(22):2755\u20138.","journal-title":"J Mater Fetal Neonatal Med."},{"issue":"2","key":"342_CR138","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000369378","volume":"38","author":"PM Honore","year":"2014","unstructured":"Honore PM, Jacobs R, De Waele E, Van Gorp V, Spapen HD. Immunoadsorption versus therapeutic plasma exchange. Will fibrinogen make the difference? Blood Purif. 2014;38(2):158\u20139.","journal-title":"Blood Purif"},{"issue":"5","key":"342_CR139","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1567-5688(09)71822-7","volume":"10","author":"A Mlynek","year":"2009","unstructured":"Mlynek A, Meurer M. Immunoadsorption in the treatment of pemphigus. Atheroscler Suppl. 2009;10(5):107\u20139.","journal-title":"Atheroscler Suppl."},{"issue":"2","key":"342_CR140","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000090659","volume":"212","author":"R Eming","year":"2006","unstructured":"Eming R, Rech J, Barth S, Kalden JR, Schuler G, Harrer T, et al. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology. 2006;212(2):177\u201387.","journal-title":"Dermatology"},{"issue":"2","key":"342_CR141","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1346-8138.2011.01376.x","volume":"39","author":"L Westermann","year":"2012","unstructured":"Westermann L, Hugel R, Meier M, Weichenthal M, Zillikens D, Glaser R, et al. Glucocorticosteroid-resistant pemphigoid gestationis: successful treatment with adjuvant immunoadsorption. J Dermatol. 2012;39(2):168\u201371.","journal-title":"J Dermatol"},{"issue":"2","key":"342_CR142","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1046\/j.1610-0387.2003.t01-1-03509.x","volume":"1","author":"S Wohrl","year":"2003","unstructured":"Wohrl S, Geusau A, Karlhofer F, Derfler K, Stingl G, Zillikens D. Pemphigoid gestationis: treatment with immunoapheresis. J Dtsch Dermatol Ges. 2003;1(2):126\u201330.","journal-title":"J Dtsch Dermatol Ges."},{"issue":"4","key":"342_CR143","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000066343","volume":"25","author":"E Dittrich","year":"2002","unstructured":"Dittrich E, Schmaldienst S, Langer M, Jansen M, Horl WH, Derfler K. Immunoadsorption and plasma exchange in pregnancy. Kidney Blood Press Res. 2002;25(4):232\u20139.","journal-title":"Kidney Blood Press Res."},{"issue":"2","key":"342_CR144","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00115-014-4239-8","volume":"86","author":"F Hoffmann","year":"2015","unstructured":"Hoffmann F, Kraft A, Heigl F, Mauch E, Koehler J, Harms L, et al. Tryptophan immunoadsorption for multiple sclerosis and neuromyelitis optica: therapy option for acute relapses during pregnancy and breastfeeding. Nervenarzt. 2015;86(2):179\u201386.","journal-title":"Nervenarzt."},{"issue":"3","key":"342_CR145","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/jdv.12772","volume":"29","author":"M Hertl","year":"2015","unstructured":"Hertl M, Jedlickova H, Karpati S, Marinovic B, Uzun S, Yayli S, et al. Pemphigus. S2 Guideline for diagnosis and treatment\u2013guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29(3):405\u201314.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"342_CR146","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1097\/BCR.0000000000000049","volume":"35","author":"N Miletta","year":"2014","unstructured":"Miletta N, Miller ME, Lam T, Chung KK, Hivnor C. The management of pemphigus vulgaris in a burn intensive care unit: a case report and treatment review. J Burn Care Res. 2014;35(5):e357\u201363.","journal-title":"J Burn Care Res"},{"issue":"5","key":"342_CR147","doi-asserted-by":"crossref","first-page":"490","DOI":"10.61872\/sdj-2016-05-05","volume":"126","author":"PS Fatori","year":"2016","unstructured":"Fatori PS, L\u00fcbbers H, vo Mandach VMU. Pregnancy and breast feeding: antibiotics, irrigation and pastes. Swiss Dent J. 2016;126(5):490\u20131.","journal-title":"Swiss Dent J"},{"key":"342_CR148","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13023-015-0332-8","volume":"10","author":"C Leroy","year":"2015","unstructured":"Leroy C, Rigot JM, Leroy M, Decanter C, Le Mapihan K, Parent AS, et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis. 2015;10:136.","journal-title":"Orphanet J Rare Dis."},{"issue":"6","key":"342_CR149","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1001\/archderm.144.6.783","volume":"144","author":"JS Lehman","year":"2008","unstructured":"Lehman JS, Mueller KK, Schraith DF. Do safe and effective treatment options exist for patients with active pemphigus vulgaris who plan conception and pregnancy? Arch Dermatol. 2008;144(6):783\u20135.","journal-title":"Arch Dermatol"},{"issue":"4","key":"342_CR150","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.det.2011.06.008","volume":"29","author":"T McPherson","year":"2011","unstructured":"McPherson T, Venning VV. Management of autoimmune blistering diseases in pregnancy. Dermatol Clin. 2011;29(4):585\u201390.","journal-title":"Dermatol Clin"},{"issue":"4","key":"342_CR151","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/phar.1385","volume":"34","author":"LL Ramoz","year":"2014","unstructured":"Ramoz LL, Patel-Shori NM. Recent changes in pregnancy and lactation labeling: retirement of risk categories. Pharmacotherapy. 2014;34(4):389\u201395.","journal-title":"Pharmacotherapy."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-018-0342-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0342-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0342-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T22:31:01Z","timestamp":1719786661000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-018-0342-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":151,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["342"],"URL":"https:\/\/doi.org\/10.1007\/s40257-018-0342-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,2]]},"assertion":[{"value":"2 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"CJK, JSSC, and VPW have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}